Skip to main content
NCBI home page
Cellular & Molecular Biology Letters logoLink to Cellular & Molecular Biology Letters
. 2006 Dec 6;12(2):162–175. doi: 10.2478/s11658-006-0062-y

N-terminal brain natriuretic propeptide levels correlate with procalcitonin and C-reactive protein levels in septic patients

Mariusz Piechota 1, Maciej Banach 2,✉, Robert Irzmański 3, Małgorzata Misztal 4, Jacek Rysz 5, Marcin Barylski 3, Magdalena Piechota-Urbańska 6, Jan Kowalski 3, Lucjan Pawlicki 3
PMCID: PMC6275983  PMID: 17149558

Abstract

The aim of this study was to find the relationship between N-terminal brain natriuretic propeptide (NT-proBNP), procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations in septic patients. This was a prospective study, performed at Medical University Hospital No. 5 in łódź. Twenty patients with sepsis and severe sepsis were included in the study. N-terminal brain natriuretic propeptide, procalcitonin and C-reactive protein concentrations, and survival were evaluated. In the whole studied group (128 measurements), the mean NT-proBNP, procalcitonin and C-reactive protein concentrations were, respectively: 140.80±84.65 pg/ml, 22.32±97.41 ng/ml, 128.51±79.05 mg/l. The correlations for the NT-proBNP level and procalcitonin and C-reactive protein levels were 0.3273 (p<0.001) and 0.4134 (p<0.001), respectively. NT-proBNP levels correlate with PCT and CRP levels in septic patients. In the survivor subgroup, the mean NT-proBNP plasma concentrations were significantly lower than in the non-survivor subgroup.

Key words: N-terminal brain natriuretic propeptide, Procalcitonin, C-reactive protein, Sepsis, Severe sepsis

Full Text

The Full Text of this article is available as a PDF (344.8 KB).

Abbreviations used

ACCP/SCCM

American College of Chest Physicians/Society of Critical Care Medicine

APACHE II score

acute physiological and chronic health evaluation ii score

BNP

brain natriuretic peptide

CRP

C-reactive protein

NT-proBNP

N-terminal brain natriuretic propeptide

PCT

procalcitonin

SIRS

systemic inflammatory response syndrome

SOFA score

sepsis-related organ failure assessment score

References

  • 1.Members of the American College of Chest Physicians/ Society of Crit Care Med Consensus Conference Committee American College of Chest Physicians/Society of Crit Care Med Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit. Care Med. 1992;20:864–874. doi: 10.1097/00003246-199206000-00025. [DOI] [PubMed] [Google Scholar]
  • 2.Ugarte H., Silva E., Mercan D., De Mendonca A., Vincent J.L. Procalcitonin as a marker of infection in the intensive care unit. Crit. Care Med. 1999;27:498–504. doi: 10.1097/00003246-199903000-00024. [DOI] [PubMed] [Google Scholar]
  • 3.Wanner G.A., Keel M., Steckholzer U., Beier W., Stocker R., Ertel W. Relationship between procalcitonin plasma levels and severity of injury, sepsis, organ failure, and mortality in injured patients. Crit. Care Med. 2000;28:950–957. doi: 10.1097/00003246-200004000-00007. [DOI] [PubMed] [Google Scholar]
  • 4.Hoffmann U., Brueckmann M., Bertsch T., Wiessner M., Liebetrau C., Lang S., Haase K.K., Borggrefe M., Huhle G. Increased plasma levels of NT-proANP and NT-proBNP as markers of cardiac dysfunction in septic patients. Clin. Lab. 2005;51:373–379. [PubMed] [Google Scholar]
  • 5.Castillo J.R., Zagler A., Carrillo-Jimenez R., Hennekens C.H. Brain natriuretic peptide: a potential marker for mortality in septic shock. Int. J. Infect. Dis. 2004;8:271–274. doi: 10.1016/j.ijid.2003.12.007. [DOI] [PubMed] [Google Scholar]
  • 6.Charpentier J., Luyt C.E., Fulla Y., Vinsonneau C., Cariou A., Grabar S., Dhainaut J.F., Mira J.P., Chiche J.D. Brain natriuretic peptide: A marker of myocardial dysfunction and prognosis during severe sepsis. Crit. Care Med. 2004;32:660–665. doi: 10.1097/01.CCM.0000114827.93410.D8. [DOI] [PubMed] [Google Scholar]
  • 7.Witthaut R., Busch C., Fraunberger P., Walli A., Seidel D., Pilz G., Stuttmann R., Speichermann N., Verner L., Werdan K. Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med. 2003;29:1696–1702. doi: 10.1007/s00134-003-1910-0. [DOI] [PubMed] [Google Scholar]
  • 8.Nijsten M.W., Olinga P., The T.H., de Vries E.G., Koops H.S., Groothuis G.M., Limburg P.C., Duis H.J., Moshage H., Hoekstra H.J., Bijzet J., Zwaveling J.H. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit. Care Med. 2000;28:586–588. doi: 10.1097/00003246-200002000-00058. [DOI] [PubMed] [Google Scholar]
  • 9.Bohuon C. A brief history of PCT. Intensive Care Med. 2000;26:146–147. doi: 10.1007/s001340051133. [DOI] [PubMed] [Google Scholar]
  • 10.Oberhoffer M., Vogelsang H., Jager L., Reinhart K. Katacalcin and calcitonin immunoreactivity in different types of leukocytes. J. Crit. Care. 1999;14:29–33. doi: 10.1016/S0883-9441(99)90005-9. [DOI] [PubMed] [Google Scholar]
  • 11.Gramm H.J., Beier W., Zimmermann J., Oedra N., Hannemann L., Boese-Ladgraf J. Procalcitonin-A biological marker of inflammatory response with prognostic properties. Clin. Intens. Care. 1995;6:71. [Google Scholar]
  • 12.Zeni F., Viallon A., Assicot M., Tardy B., Vindimian M., Page Y. Procalcitonin serum concentrations and severity of sepsis. Clin. Intens. Care. 1994;5:89–98. [Google Scholar]
  • 13.Hergert M., Lestin H.G., Scherkus M., Brikner K., Klett I., Stranz G. Procalcitonin in patients with sepsis and polytrauma. Clin. Lab. 1998;44:659–670. [Google Scholar]
  • 14.Oberhoffer M., Biterlich A., Hentschel T., Meier-Hellmann A., Vogelsang H., Reinhart K. Procalcitonin (ProCT) correlates better with the ACCP/SCCM consensus conference definitions than other specific markers of the inflammatory response. Clin. Intens. Care. 1996;7:46. [Google Scholar]
  • 15.Oberhoffer M., Vogelsang H., Rasswurm S., Hartung T., Reinhart K. Outcome prediction by traditional and new markers of inflammation in patients with sepsis. Clin. Chem. Lab. Med. 1999;37:363–368. doi: 10.1515/CCLM.1999.060. [DOI] [PubMed] [Google Scholar]
  • 16.Markuszewski L., Rysz J., Makowski M., Debska A., Pietruszynski R. C-reactive protein as a predictor of major adverse cardiac events (MACE) after percutaneous coronary intervention? Arch. Med. Sci. 2005;1:152–156. [Google Scholar]
  • 17.Povoa P., Almeida E., Moreira P., Fernandes A., Mealha R., Aragao A., Sabino H. C-reactive protein as an indicator of sepsis. Intensive Care Med. 1998;24:1052–1056. doi: 10.1007/s001340050715. [DOI] [PubMed] [Google Scholar]
  • 18.Brueckmann M., Huhle G., Lang S., Haase K.K., Bertsch T., Weiss C., Kaden J.J., Putensen C., Borggrefe M., Hoffmann U. Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation. 2005;112:527–34. doi: 10.1161/CIRCULATIONAHA.104.472050. [DOI] [PubMed] [Google Scholar]
  • 19.Chua G., Kang-Hoe L. Marked elevations in N-terminal brain natriuretic peptide levels in septic shock. Crit. Care. 2004;8:248–250. doi: 10.1186/cc2889. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Piechota M., Irzmanski R., Banach M., Barylski M., Ostrowski S., Kowalski J., Pawlicki L. Can impedance cardiography be routinely applied in patients with sepsis and severe sepsis? Arch. Med. Sci. 2006;2:114–121. [Google Scholar]
  • 21.Pinilla J.C., Hayes P., Laverty W., Arnold C., Laxdal V. The Creactive protein to prealbumin ratio correlates with the severity of multiple organ dysfunction. Surgery. 1998;124:799–805. doi: 10.1067/msy.1998.91365. [DOI] [PubMed] [Google Scholar]
  • 22.Waydhas C., Nast-Kolb D., Trupka A., Zettl R., Kick M., Wiesholler J., Schweiberer L., Jochum M. Post-traumatic inflammatory response, secondary operations, and late multiple organ failure. J. Trauma. 1996;40:624–630. doi: 10.1097/00005373-199604000-00018. [DOI] [PubMed] [Google Scholar]
  • 23.Rau B., Steinbach G., Baumgart K., Gansauge F., Grunert A., Beger H.G. Serum amyloid A versus C-reactive protein in acute pancreatitis: clinical value of an alternative acute-phase reactant. Crit. Care Med. 2000;28:736–742. doi: 10.1097/00003246-200003000-00022. [DOI] [PubMed] [Google Scholar]
  • 24.Castelli G.P., Pognani C., Meisner M., Stuani A., Bellomi D., Sgarbi L. Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction. Crit. Care Med. 2004;8:234–242. doi: 10.1186/cc2875. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Tugrul S., Esen F., Celebi S., Ozcan P.E., Akinci O., Cakar N., Telci L. Reliability of procalcitonin as a severity marker in critically ill patients with inflammatory response. Anaesth. Intensive Care. 2002;30:747–754. doi: 10.1177/0310057X0203000605. [DOI] [PubMed] [Google Scholar]
  • 26.Hergert M., Lestin H.G., Scherkus M., Brikner K., Klett I., Stranz G. Procalcitonin in patients with sepsis and polytrauma. Clin. Lab. 1998;44:659–670. [Google Scholar]
  • 27.Piechota, M., Banach, M., Irzmanski, R., Barylski, M., Piechota-Urbanska, M., Kowalski, J., Pawlicki, L. Plasma endothelin-1 levels in septic patients. J. Intensive Care Med.22 (2007), in press. [DOI] [PubMed]
  • 28.Pereira-Barretto A.C., de Oliveira M.T., Franco F.G., Cassaro-Strunz C. ProBNP for stratifying patients with heart failure. Arq. Bras. Cardiol. 2003;81:239–248. doi: 10.1590/S0066-782X2003001100004. [DOI] [PubMed] [Google Scholar]
  • 29.Mueller T., Gegenhuber A., Poelz W., Haltmayer M. Comparison of the Biomedica NT-proBNP Enzyme Immunoassay and the Roche NTproBNP Chemiluminescence Immunoassay: Implications for the Prediction of Symptomatic and Asymptomatic Structural Heart Disease. Clin. Chem. 2003;49:976–979. doi: 10.1373/49.6.976. [DOI] [PubMed] [Google Scholar]
  • 30.Banach M., Drozdz J., Okonski P., Rysz J. Immunological aspects of the statins’ function in patients with heart failure. The raport from the Annual Conference of ESC-Heart Failure 2005. Cell. Mol. Immunol. 2005;2:433–437. [PubMed] [Google Scholar]
  • 31.Prontera C., Emdin M., Zucchelli G.C., Ripoli A., Passino C., Clerico A. Analytical performance and diagnostic accuracy of a fullyautomated electrochemiluminescent assay for the N-terminal fragment of the pro-peptide of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide. Clin. Chem. Lab. Med. 2004;42:37–44. doi: 10.1515/CCLM.2004.008. [DOI] [PubMed] [Google Scholar]
  • 32.Dahlstrom U. Can natriuretic peptides be used for the diagnosis of diastolic heart failure? Eur. J. Heart Fail. 2004;6:281–287. doi: 10.1016/j.ejheart.2004.01.005. [DOI] [PubMed] [Google Scholar]
  • 33.Irzmanski, R., Banach, M., Piechota, M., Kowalski, J., Barylski, M., Cierniewski, C.S. and Pawlicki, L. Atrial, Brain Natriuretic Peptide and Endothelin-1 concentration in patients with idiopathic arterial hypertension. The dependence on the selected morphological parameters. Clin. Exp. Hypertens.29 (2007), in press. [DOI] [PubMed]
  • 34.Phua J., Lim T.K., Lee K.H. B-type natriuretic peptide: issues for the intensivist and pulmonologist. Crit. Care Med. 2005;33:2094–2113. doi: 10.1097/01.CCM.0000178351.03327.9F. [DOI] [PubMed] [Google Scholar]
  • 35.Ma K.K., Ogawa T., de Bold A.J. Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by proinflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. J. Mol. Cell. Cardiol. 2004;36:505–513. doi: 10.1016/j.yjmcc.2004.01.001. [DOI] [PubMed] [Google Scholar]
  • 36.Piechota, M., Irzmanski, R., Banach, M., Kowalski, J. and Pawlicki, L. Impedance cardiography in hemodynamic monitoring of septic patients: prospective study. Arch. Med. Sci.3 (2007), in press.
  • 37.Banach M. The role of immunological factors in the induction of apoptosis of cardiomyocytes. Drug Pol. 2003;13:50–56. [Google Scholar]

Articles from Cellular & Molecular Biology Letters are provided here courtesy of BMC

RESOURCES